ダウンロード数: 512
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
j.cllc.2011.11.001.pdf | 345.13 kB | Adobe PDF | 見る/開く |
タイトル: | Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. |
著者: | Togashi, Yosuke Masago, Katsuhiro Handa, Tomohiro Tanizawa, Kiminobu https://orcid.org/0000-0002-5719-0744 (unconfirmed) Okuda, Chiyuki Sakamori, Yuichi https://orcid.org/0000-0001-6421-7266 (unconfirmed) Nagai, Hiroki Kim, Young Hak Mishima, Michiaki |
著者名の別形: | 冨樫, 庸介 |
キーワード: | Acute exacerbation Chemotherapy Idiopathic pulmonary fibrosis Interstitial lung disease Small-cell lung cancer |
発行日: | Jul-2012 |
出版者: | Elsevier Inc. |
誌名: | Clinical lung cancer |
巻: | 13 |
号: | 4 |
開始ページ: | 304 |
終了ページ: | 311 |
抄録: | [Background] In Japan, iatrogenic acute exacerbation of interstitial lung disease (ILD) is a serious complication in patients with lung cancer and simultaneous ILD. Results of some reports suggest that patients with ILD and small-cell lung cancer (SCLC) might benefit from chemotherapy, but the influence of ILD on prognosis is unclear. [Patients and Methods] Retrospective study of patients with SCLC with or without ILD. Between April 2006 and March 2011, 122 patients with SCLC who were receiving platinum-based combination chemotherapy participated. [Results] Twenty-eight patients (23.0%) had ILD at diagnosis. Pneumonitis associated with chemotherapy, including acute exacerbation–ILD was significantly increased in patients with preexisting ILD (8/28 vs. 2/94; P = .0001). In patients receiving chemotherapy alone, response rates and median progression-free survival of first-line chemotherapy in patients with or without preexisting ILD was not significantly different (P = .26; 20/26 vs. 52/60 and P = .089; 4.4 months vs. 5.4 months, respectively). The median overall survival of all patients was 15.5 months, but those without preexisting ILD survived significantly longer (P = .0010; 17.8 months vs. 10.7 months). Multivariate analysis revealed that performance status of 0 or 1 (hazard ratio [HR] 0.19 [95% confidence interval {CI}, 0.10-0.37]; P < .0001) limited disease (HR 0.42 [95% CI, 0.23-0.73]; P = .0017), and no preexisting ILD (HR 0.36 [95% CI, 0.19-0.69]; P = .0027) were significantly associated with longer overall survival. [Conclusion]Patients with SCLC and ILD might benefit from chemotherapy, but preexisting ILD is an independent prognostic factor for poorer survival. |
著作権等: | © 2012 Elsevier Inc. This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/158292 |
DOI(出版社版): | 10.1016/j.cllc.2011.11.001 |
PubMed ID: | 22169479 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。